Showing 3981-3990 of 5231 results for "".
- Empowering the HS Community Through Wellness, Nutrition, and Compassionhttps://practicaldermatology.com/news/empowering-the-hs-community-through-wellness-nutrition-and-compassion/2485555/Wellness goes beyond skin when it comes to managing hidradenitis suppurativa (HS). In an effort to spread awareness of that concept, HS Connect founder and CEO Brindley Brooks and COO Cristina Curp took the stage at
- RE-UNITE-PN Launched to Evaluate Nemolizumab in Prurigo Nodularishttps://practicaldermatology.com/news/re-unite-pn-launched-to-evaluate-nemolizumab-in-prurigo-nodularis/2485449/A new international, non-interventional study aims to provide critical real-world data on nemolizumab’s performance in patients with moderate-to-severe prurigo nodularis (PN). The RE-UNITE-PN study (NCT06988618), sponsored by Galderma, is designed to complement pivo
- Sclerotic cGVHD Patients Show Higher Risk for Outcome Reporting Mismatchhttps://practicaldermatology.com/news/patient-reported-cgvhd-worsening-linked-to-mortality-in-sclerotic-disease/2485447/A new longitudinal cohort study published in JAMA Dermatology showed differences in frequency and importance of discordance between clinician-reported and patient-reported outcomes in cutaneous chronic graft-vs-host disease (cG
- Dr. April Armstrong Previews New Era for Oral Psoriasis Treatmentshttps://practicaldermatology.com/news/dr-april-armstrong-previews-new-era-for-oral-psoriasis-treatments/2485362/From wild chickens roaming Maui to a growing flock of groundbreaking psoriasis therapies, April W. Armstrong, MD, MPH, delivered an optimistic update on the future of plaque psoriasis treatment during a presentation at the 2026 Winter Clinical Dermatology Conference in Hawaii. “Psoriasis d
- Swann Dermatology Partners Merges with Forefront Dermatologyhttps://practicaldermatology.com/news/swann-dermatology-partners-merges-with-forefront-dermatology-in-strategic-expansion-move/2485339/Swann Dermatology Partners (SDP), a multi-location practice based in Springfield, Missouri, announced that it has officially joined Forefront Dermatology, a nationwide dermatology network backed by private equity firm Partners Group.
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- Study Links BMI and IBD Causally to Hidradenitis Suppurativahttps://practicaldermatology.com/news/mendelian-randomization-study-links-bmi-and-ibd-causally-to-hidradenitis-suppurativa/2485068/A new mendelian randomization (MR) analysis provides genetic evidence supporting a causal role for elevated body mass index (BMI) and inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS). Study researchers used gen
- First Patient Enrolled in Nemolizumab Study for Chronic Itch Without Causehttps://practicaldermatology.com/news/first-patient-enrolled-in-nemolizumab-study-for-chronic-itch-without-cause/2484883/Galderma announced the enrollment first patient in a phase II clinical trial investigating nemolizumab for the treatment of Chronic Pruritus of Unknown Origin (CPUO), according to a press release from the manufacturer. The tr
- Survey Shows Common Skin Cancer Terms Often Misunderstoodhttps://practicaldermatology.com/news/common-skin-cancer-terms-often-misunderstood-survey-finds/2484880/A research letter looking at how well patients understand commonly used terminology related to skin published in JAMA Dermatology revealed significant gaps that could hinder informed decision-making, according to the study r
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://practicaldermatology.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in